研究業績 Achievements

  1. Sasaki J, Sato A, Sasaki M, Okabe I, Kodama K, Otsuguro S, Yasuda K, Kojima H, Orba Y, Sawa H, Maenaka K, Yanagi Y, Hashiguchi T. X-206 exhibits broad-spectrum anti-β-coronavirus activity, covering SARS-CoV-2 variants and drug-resistant isolates. Antiviral Res. 2024 Dec;232:106039. doi: 10.1016/j.antiviral.2024.106039
  2. Kuwata T, Kaku Y, Biswas S, Matsumoto K, Shimizu M, Kawanami Y, Uraki R, Okazaki K, Minami R, Nagasaki Y, Nagashima M, Yoshida I, Sadamasu K, Yoshimura K, Ito M, Kiso M, Yamayoshi S, Imai M, Ikeda T, Sato K, Toyoda M, Ueno T, Inoue T, Tanaka Y, Kimura KT, Hashiguchi T, Sugita Y, Noda T, Morioka H, Kawaoka Y, Matsushita S; Genotype to Phenotype Japan (G2P-Japan) Consortium. Induction of IGHV3-53 public antibodies with broadly neutralising activity against SARS-CoV-2 including Omicron subvariants in a Delta breakthrough infection case. EBioMedicine. 2024 Dec;110:105439. doi: 10.1016/j.ebiom.2024.105439
  3. Deguchi S, Yokoi F, Takayama K. Organoids and microphysiological systems for pharmaceutical research of viral respiratory infections. Drug Metab Pharmacokinet. 2024 Nov 15;60:101041. doi: 10.1016/j.dmpk.2024.101041. Epub ahead of print. PMID: 39847975
  4. Akiba Y, Matsugo H, Kanda T, Sakai M, Makino A, Tomonaga K. A single amino acid substitution in the Borna disease virus glycoprotein enhances the infectivity titer of vesicular stomatitis virus pseudotyped virus by altering membrane fusion activity. Microbiol Immunol. 2024 Nov;68(11):381-392. doi: 10.1111/1348-0421.13172. Epub 2024 Sep 23. PMID: 39310974
  5. Yajima H, Anraku Y, Kaku Y, Kimura KT, Plianchaisuk A, Okumura K, Nakada-Nakura Y, Atarashi Y, Hemmi T, Kuroda D, Takahashi Y, Kita S, Sasaki J, Sumita H; Genotype to Phenotype Japan (G2P-Japan) Consortium; Ito J, Maenaka K, Sato K, Hashiguchi T. Structural basis for receptor-binding domain mobility of the spike in SARS-CoV-2 BA.2.86 and JN.1. Nat Commun. 2024 Oct 7;15(1):8574. doi: 10.1038/s41467-024-52808-2.
  6. Molecular and structural insights into SARS-CoV-2 evolution: from BA.2 to XBB subvariants.
    Yajima H, Nomai T, Okumura K, Maenaka K; Genotype to Phenotype Japan (G2P-Japan) Consortium; Ito J, Hashiguchi T, Sato K. Molecular and structural insights into SARS-CoV-2 evolution: from BA.2 to XBB subvariants. mBio. 2024 Oct 16;15(10):e0322023. doi: 10.1128/mbio.03220-23
  7. Tsujino S, Deguchi S, Nomai T, Padilla-Blanco M, Plianchaisuk A, Wang L, Begum MM, Uriu K, Mizuma K, Nao N, Kojima I, Tsubo T, Li J, Matsumura Y, Nagao M, Oda Y, Tsuda M, Anraku Y, Kita S, Yajima H, Sasaki-Tabata K, Guo Z, Hinay AA Jr, Yoshimatsu K, Yamamoto Y, Nagamoto T, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Nasser H, Jonathan M, Putri O, Kim Y, Chen L, Suzuki R, Tamura T, Maenaka K, Irie T, Matsuno K, Tanaka S, Ito J, Ikeda T, Takayama K, Zahradnik J, Hashiguchi T, Fukuhara T, Sato K; Genotype to Phenotype Japan (G2P‐Japan) Consortium. Virological characteristics of the SARS-CoV-2 Omicron EG.5.1 variant. Microbiol Immunol. 2024 Sep;68(9):305-330. doi: 10.1111/1348-0421.13165.
  8. Yokoi F, Deguchi S, Watanabe Y, Takayama K. Establishment of an ulcerative colitis model using colon organoids derived from human induced pluripotent stem cells. iScience. 2024 Sep 26;27(10):111049. doi: 10.1016/j.isci.2024.111049. PMID: 39435148; PMCID: PMC11492162.
  9. Iida T, Ando J, Yoshimura M, Makino A, Nakano M, Kogo Y, Shinoda H, Toyoda M, Noda T, Watanabe R. Portable wide-field femtoliter-chamber imaging system for point-of-care digital bioanalysis. iScience. 27(9):110868. 2024 Sep
  10. Fukuhara H, Yumoto K, Sako M, Kajikawa M, Ose T, Kawamura M, Yoda M, Chen S, Ito Y, Takeda S, Mwaba M, Wang J, Hashiguchi T, Kamishikiryo J, Maita N, Kitatsuji C, Takeda M, Kuroki K, Maenaka K. Glycan-shielded homodimer structure and dynamical features of the canine distemper virus hemagglutinin relevant for viral entry and efficient vaccination. Elife. 2024 Jul 24;12:RP88929. doi: 10.7554/eLife.88929.
  11. Sakai M, Masuda Y, Tarumoto Y, Aihara N, Tsunoda Y, Iwata M, Kamiya Y, Komorizono R, Noda T, Yusa K, Tomonaga K, Makino A. Genome-scale CRISPR-Cas9 screen identifies host factors as potential therapeutic targets for SARS-CoV-2 infection. iScience. 2024 Jul 8;27(8):110475. doi: 10.1016/j.isci.2024.110475. eCollection 2024 Aug 16. PMID: 39100693
  12. Iwai N, Akaki K, Hia F, Li W, Yoshinaga M, Mino T, Takeuchi O. UPF1 plays critical roles in early B cell development. Nat Commun. 2024 Jul 9;15(1):5765
  13. Zhang Z, Takenaga T, Fehling SK, Igarashi M, Hirokawa T, Muramoto Y, Yamauchi K, Onishi C, Nakano M, Urata S, Groseth A, Strecker T, Noda T. Hexestrol, an estrogen receptor agonist, inhibits Lassa virus entry. J Virol. 98(7):e0071424. 2024 May
  14. Paul R, Kasahara K, Sasaki J, Pérez JF, Matsunaga R, Hashiguchi T, Kuroda D, Tsumoto K. Unveiling the affinity-stability relationship in anti-measles virus antibodies: a computational approach for hotspots prediction. Front Mol Biosci. 2024 Mar 1;10:1302737. doi: 10.3389/fmolb.2023.1302737

  15. Hirabayashi A, Muramoto Y, Takenaga T, Tsunoda Y, Wakazaki M, Sato M, Fujita-Fujiharu Y, Nomura N, Yamauchi K, Onishi C, Nakano M, Toyooka K, Noda T. Coatomer complex I is required for the transport of SARS-CoV-2 progeny virions from the endoplasmic reticulum-Golgi intermediate compartment. mBio. e0333124. 2024 Jan